217 related articles for article (PubMed ID: 37566183)
1. The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.
Alsmadi MM; Jaradat MM; Obaidat RM; Alnaief M; Tayyem R; Idkaidek N
AAPS PharmSciTech; 2023 Aug; 24(6):172. PubMed ID: 37566183
[TBL] [Abstract][Full Text] [Related]
2. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.
Idkaidek N; Hawari F; Dodin Y; Obeidat N
Drug Res (Stuttg); 2021 May; 71(5):250-256. PubMed ID: 33378773
[TBL] [Abstract][Full Text] [Related]
3. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
Tai TT; Wu TJ; Wu HD; Tsai YC; Wang HT; Wang AM; Shih SF; Chen YC
Clin Transl Sci; 2021 Jan; 14(1):132-136. PubMed ID: 33135382
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
Ruiz S; Concordet D; Lanot T; Georges B; Goudy P; Baklouti S; Mané C; Losha E; Vinour H; Rousset D; Lavit M; Minville V; Conil JM; Gandia P
Int J Antimicrob Agents; 2021 Feb; 57(2):106247. PubMed ID: 33259916
[TBL] [Abstract][Full Text] [Related]
5. Development, In Vitro Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous Carriers Loaded with Cisplatin for Lung Cancer Treatment.
Alsmadi MM; Obaidat RM; Alnaief M; Albiss BA; Hailat N
AAPS PharmSciTech; 2020 Jul; 21(5):191. PubMed ID: 32661587
[TBL] [Abstract][Full Text] [Related]
6. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling.
Rowland Yeo K; Zhang M; Pan X; Ban Ke A; Jones HM; Wesche D; Almond LM
Clin Pharmacol Ther; 2020 Nov; 108(5):976-984. PubMed ID: 32531808
[TBL] [Abstract][Full Text] [Related]
7. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
[TBL] [Abstract][Full Text] [Related]
8. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.
Kannan R; Przekwas A
Int J Numer Method Biomed Eng; 2020 Dec; 36(12):e3403. PubMed ID: 33029911
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Zahr N; Urien S; Llopis B; Pourcher V; Paccoud O; Bleibtreu A; Mayaux J; Gandjbakhch E; Hekimian G; Combes A; Benveniste O; Saadoun D; Allenbach Y; Pinna B; Cacoub P; Funck-Brentano C; Salem JE
Therapie; 2021; 76(4):285-295. PubMed ID: 33558079
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human.
Alsmadi MM; Al-Daoud NM; Obaidat RM; Abu-Farsakh NA
AAPS PharmSciTech; 2022 May; 23(5):148. PubMed ID: 35585214
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers.
Hawari F; Dodin Y; Tayyem R; Najjar S; Kakish H; Fara MA; Zou'bi AA; Idkaidek N
J Aerosol Med Pulm Drug Deliv; 2023 Apr; 36(2):76-81. PubMed ID: 36637803
[No Abstract] [Full Text] [Related]
12. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.
Albariqi AH; Chang RYK; Tai W; Ke WR; Chow MYT; Tang P; Kwok PCL; Chan HK
J Aerosol Med Pulm Drug Deliv; 2021 Feb; 34(1):20-31. PubMed ID: 33179983
[No Abstract] [Full Text] [Related]
13. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions.
Kolli AR; Semren TZ; Bovard D; Majeed S; van der Toorn M; Scheuner S; Guy PA; Kuczaj A; Mazurov A; Frentzel S; Calvino-Martin F; Ivanov NV; O'Mullane J; Peitsch MC; Hoeng J
AAPS J; 2022 Feb; 24(1):33. PubMed ID: 35132508
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
17. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.
Zhang M; Yao X; Hou Z; Guo X; Tu S; Lei Z; Yu Z; Liu X; Cui C; Chen X; Shen N; Song C; Qiao J; Xiang X; Li H; Liu D
Front Pharmacol; 2020; 11():585021. PubMed ID: 33643034
[TBL] [Abstract][Full Text] [Related]
18. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.
Karatza E; Ismailos G; Marangos M; Karalis V
Xenobiotica; 2021 Feb; 51(2):127-138. PubMed ID: 32933365
[TBL] [Abstract][Full Text] [Related]
19. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial.
Stoll F; Blank A; Mikus G; Czock D; Foerster KI; Hermann S; Häußler K; Muhareb A; Hummler S; Weiss J; Burhenne J; Haefeli WE
Trials; 2020 Jun; 21(1):584. PubMed ID: 32600363
[TBL] [Abstract][Full Text] [Related]
20. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
